2025 Q3 -tulosraportti
66 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,15 %Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 440 926
Myynti
Määrä
2 442 733
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 11 | - | - | ||
| 100 | - | - | ||
| 109 | - | - | ||
| 12 | - | - |
Ylin
389,8VWAP
Alin
369VaihtoMäärä
3 408,4 8 947 255
VWAP
Ylin
389,8Alin
369VaihtoMäärä
3 408,4 8 947 255
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.2. |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·4 t sittenDo we believe that we are heading towards the high mountains again?
·6 t sittenTrump's Greenland pressure poses a potential risk for Novo Nordisk through tariff threats against Danish goods. Denmark rejects the sale, but Trump threatens tariffs if the demand is not met, which could raise costs for NOVO-B's export of Ozempic and Wegovy to the USA even with American production in place. Novo Nordisk's CEO recently participated in crisis talks with Denmark's Prime Minister.
·5 t sittenDenmark must enter into an agreement with the USA. Denmark faces significant economic challenges, including rising defense expenditures from NATO rearmament, climate taxes, and large compensation of approximately 30 billion Danish kroner to mink owners and related industries, and many other expenses for the welfare society (with an aging population). Note that Denmark does not own Greenland according to the Self-Government Act. Those who do not want a USA takeover of Greenland are probably those who benefit from the Danish welfare society in Greenland. Furthermore, we finance the infrastructure, hospitals, the prison system, and the police, which costs every Danish taxpayer thousands of kroner. All other countries we can compare ourselves with have long since given up their colonies. Greenland belongs to North America, as Greenlanders belong to the Inuit, who are found in North America. At the same time, politicians do not want to lose prestige by giving up Greenland. The USA can at any time cripple the Danish economy and split the EU and NATO. What surprises me is that the media has not focused on the fact that if Trump's administration wants Greenland, he can use economic pressure and targeted tariffs against, for example, Germany, France, or Italy, and some governments will be tempted to acquiesce to protect their own export interests, especially as long as there are no military conflicts. So the question is, where is the solidarity or cohesion in the EU and NATO? Furthermore, he can use tariffs on Danish export goods to the USA. And not just medicinal/pharma, but also large Danish companies like Lego, Danfosse, Grundfoss, and many other Danish companies that export to the USA.- ·7 t sitten · MuokattuNew triggers await. The US launch of the Wegovy pill will be an important growth driver in 2026 followed by cagrisema in 2027, writes the analysis firm in a new analysis under the headline "the pill war." Weight loss drug cagrisma is being developed as a potential successor to wegovy, and data for the drug is expected in a comparison study with competitor Eli Lilly's drug Zepbound in the first quarter of this year. Data will be a decisive trigger for the stock according to the analysis, which is positive on the stock.
8 t sitten8 t sittenAt Eli Lilly & Co (LLY), the insider activity was dominated by one massive move from a major stakeholder. Significant shareholder sold 292,148 shares of Eli Lilly & Co stock in a transaction totaling an eye-catching $322,379,685. This kind of large block sale by a significant shareholder can be driven by portfolio rebalancing, funding needs for philanthropic missions, or strategic asset allocation rather than company-specific concerns, but the sheer scale—over $322 million worth of stock—naturally commands the attention of institutional investors and analysts.
·10 t sittenSelling a part of Novo now. The company is solid and dominates the market, but the price has already risen a lot, and I'm taking some profit and reducing risk. No doubt that they still have growth potential, but I choose to balance the portfolio.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
66 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,15 %Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenDo we believe that we are heading towards the high mountains again?
- ·6 t sittenTrump's Greenland pressure poses a potential risk for Novo Nordisk through tariff threats against Danish goods. Denmark rejects the sale, but Trump threatens tariffs if the demand is not met, which could raise costs for NOVO-B's export of Ozempic and Wegovy to the USA even with American production in place. Novo Nordisk's CEO recently participated in crisis talks with Denmark's Prime Minister.·5 t sittenDenmark must enter into an agreement with the USA. Denmark faces significant economic challenges, including rising defense expenditures from NATO rearmament, climate taxes, and large compensation of approximately 30 billion Danish kroner to mink owners and related industries, and many other expenses for the welfare society (with an aging population). Note that Denmark does not own Greenland according to the Self-Government Act. Those who do not want a USA takeover of Greenland are probably those who benefit from the Danish welfare society in Greenland. Furthermore, we finance the infrastructure, hospitals, the prison system, and the police, which costs every Danish taxpayer thousands of kroner. All other countries we can compare ourselves with have long since given up their colonies. Greenland belongs to North America, as Greenlanders belong to the Inuit, who are found in North America. At the same time, politicians do not want to lose prestige by giving up Greenland. The USA can at any time cripple the Danish economy and split the EU and NATO. What surprises me is that the media has not focused on the fact that if Trump's administration wants Greenland, he can use economic pressure and targeted tariffs against, for example, Germany, France, or Italy, and some governments will be tempted to acquiesce to protect their own export interests, especially as long as there are no military conflicts. So the question is, where is the solidarity or cohesion in the EU and NATO? Furthermore, he can use tariffs on Danish export goods to the USA. And not just medicinal/pharma, but also large Danish companies like Lego, Danfosse, Grundfoss, and many other Danish companies that export to the USA.
- ·7 t sitten · MuokattuNew triggers await. The US launch of the Wegovy pill will be an important growth driver in 2026 followed by cagrisema in 2027, writes the analysis firm in a new analysis under the headline "the pill war." Weight loss drug cagrisma is being developed as a potential successor to wegovy, and data for the drug is expected in a comparison study with competitor Eli Lilly's drug Zepbound in the first quarter of this year. Data will be a decisive trigger for the stock according to the analysis, which is positive on the stock.
- 8 t sitten8 t sittenAt Eli Lilly & Co (LLY), the insider activity was dominated by one massive move from a major stakeholder. Significant shareholder sold 292,148 shares of Eli Lilly & Co stock in a transaction totaling an eye-catching $322,379,685. This kind of large block sale by a significant shareholder can be driven by portfolio rebalancing, funding needs for philanthropic missions, or strategic asset allocation rather than company-specific concerns, but the sheer scale—over $322 million worth of stock—naturally commands the attention of institutional investors and analysts.
- ·10 t sittenSelling a part of Novo now. The company is solid and dominates the market, but the price has already risen a lot, and I'm taking some profit and reducing risk. No doubt that they still have growth potential, but I choose to balance the portfolio.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 440 926
Myynti
Määrä
2 442 733
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 11 | - | - | ||
| 100 | - | - | ||
| 109 | - | - | ||
| 12 | - | - |
Ylin
389,8VWAP
Alin
369VaihtoMäärä
3 408,4 8 947 255
VWAP
Ylin
389,8Alin
369VaihtoMäärä
3 408,4 8 947 255
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.2. |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
66 päivää sitten54 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.2. |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
Datan lähde: Quartr, FactSet
3,75 DKK/osake
Viimeisin osinko
3,15 %Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenDo we believe that we are heading towards the high mountains again?
- ·6 t sittenTrump's Greenland pressure poses a potential risk for Novo Nordisk through tariff threats against Danish goods. Denmark rejects the sale, but Trump threatens tariffs if the demand is not met, which could raise costs for NOVO-B's export of Ozempic and Wegovy to the USA even with American production in place. Novo Nordisk's CEO recently participated in crisis talks with Denmark's Prime Minister.·5 t sittenDenmark must enter into an agreement with the USA. Denmark faces significant economic challenges, including rising defense expenditures from NATO rearmament, climate taxes, and large compensation of approximately 30 billion Danish kroner to mink owners and related industries, and many other expenses for the welfare society (with an aging population). Note that Denmark does not own Greenland according to the Self-Government Act. Those who do not want a USA takeover of Greenland are probably those who benefit from the Danish welfare society in Greenland. Furthermore, we finance the infrastructure, hospitals, the prison system, and the police, which costs every Danish taxpayer thousands of kroner. All other countries we can compare ourselves with have long since given up their colonies. Greenland belongs to North America, as Greenlanders belong to the Inuit, who are found in North America. At the same time, politicians do not want to lose prestige by giving up Greenland. The USA can at any time cripple the Danish economy and split the EU and NATO. What surprises me is that the media has not focused on the fact that if Trump's administration wants Greenland, he can use economic pressure and targeted tariffs against, for example, Germany, France, or Italy, and some governments will be tempted to acquiesce to protect their own export interests, especially as long as there are no military conflicts. So the question is, where is the solidarity or cohesion in the EU and NATO? Furthermore, he can use tariffs on Danish export goods to the USA. And not just medicinal/pharma, but also large Danish companies like Lego, Danfosse, Grundfoss, and many other Danish companies that export to the USA.
- ·7 t sitten · MuokattuNew triggers await. The US launch of the Wegovy pill will be an important growth driver in 2026 followed by cagrisema in 2027, writes the analysis firm in a new analysis under the headline "the pill war." Weight loss drug cagrisma is being developed as a potential successor to wegovy, and data for the drug is expected in a comparison study with competitor Eli Lilly's drug Zepbound in the first quarter of this year. Data will be a decisive trigger for the stock according to the analysis, which is positive on the stock.
- 8 t sitten8 t sittenAt Eli Lilly & Co (LLY), the insider activity was dominated by one massive move from a major stakeholder. Significant shareholder sold 292,148 shares of Eli Lilly & Co stock in a transaction totaling an eye-catching $322,379,685. This kind of large block sale by a significant shareholder can be driven by portfolio rebalancing, funding needs for philanthropic missions, or strategic asset allocation rather than company-specific concerns, but the sheer scale—over $322 million worth of stock—naturally commands the attention of institutional investors and analysts.
- ·10 t sittenSelling a part of Novo now. The company is solid and dominates the market, but the price has already risen a lot, and I'm taking some profit and reducing risk. No doubt that they still have growth potential, but I choose to balance the portfolio.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 440 926
Myynti
Määrä
2 442 733
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 11 | - | - | ||
| 100 | - | - | ||
| 109 | - | - | ||
| 12 | - | - |
Ylin
389,8VWAP
Alin
369VaihtoMäärä
3 408,4 8 947 255
VWAP
Ylin
389,8Alin
369VaihtoMäärä
3 408,4 8 947 255
Välittäjätilasto
Dataa ei löytynyt